| Data Presented at ECCMID 2012 Meeting RADNOR, Pa., April 2, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat serious acute-care conditions, announced today that its lead defensin-mimetic antibiotic, PMX-30063, has shown activity against 1,000 worldwide strains of Gram-positive staphylococci and streptococci clinical isolates, including strains resistant to linezolid, daptomycin, and methicillin. The data were p...continued PYMX biotech antibiotics Drugs |
SmallCapUpdates provides the latest news and alerts on stocks for you. If you are looking for the latest on stocks in clean energy, medical innovation, mining, biotech, nanotech, renewable energy, internet technology or in emerging markets.
Pages
▼
No comments:
Post a Comment